2007-08-28-¨ÅÀùµo¥Í²v¤U­°¾É¦]©ó±Ä¥ÎHRTªº°±¸g°ü¤k¤j´T´î¤Ö

®Ú¾Ú³Ì·s¡¦¥þ¬üÀù¯g¨ó·|¡¦´Á¥Z³ø§i«ü¥X,¥Ñ©ó°±¸g°ü¤k±Ä¥Î¡¦²üº¸»X´À¥NÀøªk¡¦(Hormone Replacement Therapy; HRT)ªº¼Æ¥ØÆJ´î,¾É­P«I²¤©Ê¨ÅÀùµo¥Í²v¬Æ¦Ü¬O¨ÅÀù¿zÀ˲v¤]ÀH¤§¤j´T¤U­°.  

¨Ó¦Ûª÷¤s°h¥î­x¤HÂåÀø¤¤¤ß»P¥[¦{¤j¾ÇªºDr. Karla Kerlikowskeªí¥Ü:¡¨³o¬O¤@¶µ¥O¤H®¶¾Äªº®ø®§¡K..³o¤]·N¨ýµÛµu®É¶¡¨Ï¥ÎHRT卽¥ß¨è°±¤îªº°ü¤k,¨ä¿©±w¨ÅÀùªº¾÷²v»P±q¥¼¨Ï¥ÎHRTªº°ü¤k¬O¤@¼Ë§Cªº.¡¨

¦Û±q2000¦~ªì,¦³¨Ç¬ã¨s³ø§i«ü¥X¦P®É¨Ï¥Î»Û¿E¯À(estrogen)»P¶ÀÅé¿E¯À(progestin)µ²¦XÀøªkªº°ü¤k¿©±w¨ÅÀùªº¾÷²v¤ñ³æ¤@¨Ï¥Î»Û¿E¯Àªº­·ÀI­n°ª«Ü¦h;±q¦¹,°±¸g°ü¤k±Ä¥Î¡¦²üº¸»X´À¥NÀøªk¡¦ (HRT)ªº¼Æ¥Ø´N¤w¶}©lºCºC´î¤Ö. ¤×¨ä¬O¦b2002¦~7¤ë,¬ü°ê°ê½Ã°|ªº°ü¤k°·±d«P¶i­p¹º(women health initiative, WHI)¤½§G¤F¤@½g¬ã¨sµ²ªGÅã¥Ü²üº¸»X´À¥NÀøªk¥i¯à·|¾É­P¦­´Á¤ß¦åºÞ¯e¯f­·ÀI¼W¥[;¦Ü¦¹,±Ä¥ÎHRTªº°ü¤k§ó¬O¤j´TÆJ´î.

Kerlikowske»P¨ä¦P¤¯ÂÇ¥ÑÀ˵ø¨Ò¦æ¨Å¸¢X¥úÀË´ú(mammography)¸ê®Æ¥Î¥H½T»{°±¸g°ü¤kHRTªº¨Ï¥Î²v¤Î¨ÅÀù¿©±w²v¬O§_¦³¦P®É¤U­°ªºÁͶÕ.

¦o©Ò»â¾Éªº¹Î¶¤¦@À˵ø¤F¶W¹L600,000¦W(¦~ÄÖ¤¶©ó50-59·³)±µ¨ü¨Ò¦æ¨Å¸¢X¥úÀË´úªº°ü¤k¸ê®Æ,Á`­p¦³3238¦W°ü¤k³QÀË´ú¥X¿©±w¨ÅÀù. ³ø§i¼Æ¾ÚÅã¥Üª½¨ì2001¦~,°Ñ¥[ªÌ¿©±w¡¦»Û¿E¯À¨üÅé¶§©Ê¨ÅÀù¡¦(estrogen receptor-positive invasive cancer)ªº¾÷²v¤@ª½³£«Üí©w;µM¦Ó±q2001¨ì2003¦~¶¡,°Ñ¥[ªÌªº¨ÅÀùµo¥Í²v«h³v¦~¤U­°13%. ¦¹¥~,­P©R©Ê§ó°ªªº¡¦»Û¿E¯À¨üÅé³±©Ê¨ÅÀù¡¦(estrogen receptor-negative invasive cancer)µo¥Í²v¦b³o´Á¶¡«h¨S¦³§ïÅÜ.  

¬ã¨sÁ`µ²«ü¥X:¡¨§Ú­Ìªºµ²ªGÅã¥Ü´î¤Ö¨Ï¥Î²üº¸»X´À¥NÀøªk¡]HRT¡^½T¹ê¥i¥H¦³§U©ó­°§C°±¸g°ü¤k¿©±w¨ÅÀùªº¾÷²v.¡¨ KerlikowskeÁÙ±j½Õ:¡¨¹ï©ó¨º¨Ç¥²»Ý±Ä¥Î»Û¿E¯À¤Î¶ÀÅé¿E¯À¨Ó±±¨î¡¦¼ö¼é¬õ¡¦(hot flush)¯gª¬ªº°±¸g°ü¤k¦Ó¨¥,±Ä¥Îªº®É¶¡À³¸Ó¾¨¥i¯à·Uµu·U¦n.¡¨

°Ñ¦Ò¸ê®Æ: (1) ¡¨Breast cancer decline attributed to drop in HRT¡¨(2007-08-24/Reuters Health)

http://www.reutershealth.com/en/index.html

(2)¡¨ Decline in HRT Use Linked to Drop in Breast Cancer¡¨(2007-04-18/ HealthDay News)

http://www.hon.ch/News/HSN/603824.html